Abstract
The need for a simple method of examining the early postnatal development of mouse models of human neurodevelopmental disorders has become evident. The following method for evaluating the developmental milestones of newborn mice allows for fast throughput of large numbers of mice in a battery of tests that examines weight gain and the reflexes and coordinated movements that are expressed at differing periods throughout the first 21 days of life. Sophisticated equipment is not required, and the measures focus on the day of first appearance of a developmental sign, reflex, or coordinated movement.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Branchi, I., Bichler, Z., Berger-Sweeney, J., and Ricceri, L. Animal models of mental retardation: From gene to cognitive function. Neurosci. Biobehav. Rev., 2003; 27: 141–153.
Wu, J.Y., Henins, K.A., Gressens, P., Gozes, I., Fridkin, M., Brenneman, D.E., and Hill, J.M. Neurobehavioral development of neonatal mice following blockade of VIP during the early embryonic period. Peptides, 1997; 18: 1131–1137.
Hill, J.M., Gozes, I., Hill, J.L., Fridkin, M., and Brenneman, D.E. Vasoactive intestinal peptide antagonist retards the development of neonatal behaviors in the rat. Peptides, 1991; 12: 187–192.
Hill, J.M., Mervis, R.F., Avidor, R., Moody, T.W., and Brenneman, D.E. HIV envelope protein-induced neuronal damage and retardation of behavioral development in rat neonates. Brain Res., 1993; 603: 222–233.
Fox, W.M. Reflex-ontogeny and behavioral development of the mouse. Anim. Behav., 1965; 13: 234–241.
Altman, J., and Sudarshan, K. Postnatal development of locomotion in the laboratory rat. Anim. Behav., 1975; 23: 896–920.
Zorrilla, E.P. Multiparous species present problems (and possibilities) to developmentalists. Dev. Psychobiol., 1997; 30: 141–150.
Hill, J.M. Vasoactive intestinal peptide in neurodevelopmental disorders: Therapeutic potential. Curr. Pharm. Design (in publication).
Epstein, C.J. Down syndrome (trisomy 21). In The Metabolic Basis of Inherited Disease, C.R. Shriver, A.L. Beaudet, W.S. Sly, and V. Valle, eds. McGraw-Hill, New York, 1989, pp. 291–326.
Gozes, I., Bachar, M., Bardea, A., Davidson, A., Rubinraut, S., Fridkin, M., and Giladi, E. Protection against developmental retardation in apolipoptrotein E-deficient mice by a fatty neuropeptide: Implications for early treatment of Alzheimer’s disease. J. Neurobiol., 1997; 33: 329–342.
Gozes, I., Bachar, M., Bardea, A., Davidson, A., Rubinraut, S., and Fridkin, M. Protection against developmental deficiencies by a lipophilic VIP analogue. Neurochem. Res., 1998; 23: 689–693.
Branchi, I., and Ricceri, L. Transgenic and knock-out mouse pups: The growing need for behavioral analysis. Genes Brain Behav., 2002; 1: 135–141.
Gozes, I., McCune, S.K., Jacobson, L., Warren, D., Moody, T.W., Fridkin, M., and Brenneman, D.E. An antagonist to vasoactive intestinal peptide affects cellular functions in the central nervous system. J. Pharmacol. Exp. Ther., 1991; 257: 959–966.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2008 Humana Press Inc.
About this protocol
Cite this protocol
Hill, J.M., Lim, M.A., Stone, M.M. (2008). Developmental Milestones in the Newborn Mouse. In: Gozes, I. (eds) Neuropeptide Techniques. Neuromethods, vol 39. Humana Press. https://doi.org/10.1007/978-1-60327-099-1_10
Download citation
DOI: https://doi.org/10.1007/978-1-60327-099-1_10
Publisher Name: Humana Press
Print ISBN: 978-1-58829-468-5
Online ISBN: 978-1-60327-099-1
eBook Packages: Springer Protocols